|
Coronary Artery Disease
|
0.340 |
Biomarker
|
disease |
BEFREE |
However, there was no considerable difference in the mRNA levels of Homer1, IL-1β, and TNF-α among AMI, UAP, and SAP three subgroups of CAD.
|
25551602 |
2014 |
|
Coronary Artery Disease
|
0.340 |
Biomarker
|
disease |
BEFREE |
MIF levels were significantly increased in ACS compared to stable CAD and healthy control (ACS: median 2.85; IQR 3.52 ng/ml; versus SAP: median 1.22; IQR 2.99 ng/ml; versus healthy control: median 0.10; IQR 0.09 ng/ml, p < 0.001).
|
25463068 |
2014 |
|
Coronary Artery Disease
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
We measured baseline sEPCR levels in 1673 individuals with CAD (521 with acute coronary syndrome [ACS] and 1152 with stable angina pectoris [SAP]) from the AtheroGene cohort.
|
23136988 |
2012 |
|
Coronary Artery Disease
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
At both the mRNA and protein levels, ubiquitin expression was higher in patients with CAD than in controls, and patients with AMI had a much higher expression of ubiquitin (at both the mRNA and protein levels) than those with SAP and UAP.
|
19094431 |
2009 |
|
Coronary Artery Disease
|
0.340 |
Biomarker
|
disease |
CTD_human |
Elevated C-reactive protein levels are associated with endothelial dysfunction in chronic cocaine users.
|
12714198 |
2003 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
In mice dosed with SAP there was negligible hematotoxicity, while cardiac function measurements showed a reduction in the percentage left ventricular fractional shortening compared to vehicle treated animals.In conclusion, SAP is a novel rationally designed conjugatable small antiangiogenic molecule, efficacious in preclinical models of breast cancer.
|
28422745 |
2017 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
Mechanism of irradiation-induced mammary cancer metastasis: A role for SAP-dependent Mkl1 signaling.
|
25999144 |
2015 |
|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
This study highlights a crucial role for the transcriptional regulator Mkl1 and its SAP domain during breast cancer progression.
|
24495796 |
2014 |
|
Malignant neoplasm of breast
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Liver carcinoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Discrimination of tumorigenic triazole conazoles from phenobarbital by transcriptional analyses of mouse liver gene expression.
|
19363144 |
2009 |
|
Liver carcinoma
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
In this study, we compared the anti-cancer activity of PTX-2 in order to further test the status of p53 using two well-known hepatocarcinoma cell lines, p53-deficient Hep3B and p53-wild-type HepG2.
|
18202802 |
2008 |
|
Liver neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Evaluation of plasma carcinogenic markers in rat hepatic tumors models induced by rat hepatoma N1-S1 cells and benzo[a]pyrene.
|
20195826 |
2010 |
|
Malignant neoplasm of liver
|
0.300 |
Biomarker
|
disease |
CTD_human |
Evaluation of plasma carcinogenic markers in rat hepatic tumors models induced by rat hepatoma N1-S1 cells and benzo[a]pyrene.
|
20195826 |
2010 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
|
16129801 |
2005 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
|
16129801 |
2005 |
|
Left-Sided Heart Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
|
16129801 |
2005 |
|
Heart Failure, Right-Sided
|
0.300 |
Biomarker
|
disease |
CTD_human |
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
|
16129801 |
2005 |
|
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
|
16129801 |
2005 |
|
Heart Decompensation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
|
16129801 |
2005 |
|
Coronary Arteriosclerosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Elevated C-reactive protein levels are associated with endothelial dysfunction in chronic cocaine users.
|
12714198 |
2003 |
|
Epstein-Barr Virus Infections
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Epstein-Barr virus (EBV) infection was significantly more common in SAP-deficient 10/13 (76.9%) than XIAP-deficient 2/7 (28.6%) patients, as was hypogammaglobulinemia (10/13 (76.9%) vs. 1/7 (14.3%)).
|
31754776 |
2020 |
|
X-Linked Lymphoproliferative Disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HSCT is the only curative therapy for XLP and this therapy should be urgently considered.What is Known:• SAP and XIAP deficiencies share common clinical feature, HLH, whereas they also have their own specific manifestations.• IBD affects 25-30% of XIAP-deficient patients, which has been reported in other countries especially in European country and Japan.What is New:• This is the largest patient cohort study of XLP in China.• We firstly summarized the clinical features and outcomes of Chinese XIAP-deficient patients and found only 1 in 22 patients developed IBD and diet background may contribute to it; Asian SAP-deficient patients carrying SH2D1A R55X mutation were more prone to HLH.
|
31754776 |
2020 |
|
X-Linked Lymphoproliferative Disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Defective signaling via 2B4 due to mutations in signaling adaptor SAP contributes to X-linked lymphoproliferative Disease (XLP).
|
30347240 |
2019 |
|
X-Linked Lymphoproliferative Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, SAP deficiency causes X-linked lymphoproliferative disease with multiple immune defects including a lack of circulating NKT cells.
|
31293596 |
2019 |
|
X-Linked Lymphoproliferative Disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In human patients with X-linked lymphoproliferative (XLP) disease, which is caused by SAP mutations, SFRs alternatively bind other inhibitory SH2 domain-containing molecules to suppress immune cell activation and development.
|
30911116 |
2019 |